Haisco Pharmaceutical’s Market‑Approval Milestone for Ciprocopan Succinate Tablets

Haisco Pharmaceutical Group Co., Ltd. (SZ: 002653) has secured the National Medical Products Administration (NMPA) approval for its first‑in‑class, once‑daily oral complement factor B inhibitor, Ciprocopan Succinate Tablets (HSK39297). The drug, targeted at adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who are complement‑inhibitor‑naïve, represents the company’s fifth Class 1 innovative product approved in China.

Strategic Significance

  1. Therapeutic Innovation Ciprocopan is the world’s first oral complement factor B inhibitor. Its once‑daily dosing delivers a convenience advantage over current intravenous or twice‑daily regimens, positioning Haisco as a pioneer in complement‑mediated disease therapeutics.

  2. Portfolio Expansion With a drug portfolio spanning hepatobiliary, anti‑infective, and nutrition products, this approval diversifies Haisco’s revenue streams and solidifies its standing as a leading Chinese innovator in the pharmaceutical sector.

  3. Market Timing The approval coincides with a broader regulatory push in China to fast‑track Class 1 innovations through priority review pathways. Haisco’s alignment with these policy currents augurs well for future approvals.

Financial Impact

  • Revenue Growth The company’s 2026 first‑half earnings outlook, released on July 20, projected net profit of 7.9 – 8.7 billion CNY— a 513%–575% year‑on‑year increase— largely driven by sales of innovative drugs and new licensing agreements. The Ciprocopan launch is expected to contribute materially to this momentum.

  • Profitability Even after a 50%+ rise in R&D expenses, Haisco maintained robust net‑profit growth, underscoring efficient capital deployment and a high return on R&D investment.

  • Valuation Context With a market capitalization of approximately 79.4 billion CNY and a price‑earnings ratio of 103.86, Haisco is trading at a premium reflective of its innovation pipeline and regulatory successes. The new approval is likely to support continued upside in valuation multiples.

Forward Outlook

  • Commercial Roll‑out Haisco has announced plans for a nationwide launch, leveraging its established distribution network across China. Early sales data will determine the drug’s market share against existing complement‑inhibitor therapies.

  • Pipeline Leverage The company’s broad clinical program in PNH and other complement‑mediated diseases positions it to capture additional approvals, potentially reinforcing its leadership in this niche therapeutic area.

  • Strategic Partnerships Recent licensing agreements suggest a growing trend toward external collaborations. Successful monetization of these deals, contingent on milestone achievements, will further strengthen the company’s financial trajectory.

In sum, the NMPA approval of Ciprocopan Succinate Tablets marks a pivotal moment for Haisco Pharmaceutical. It validates the company’s scientific expertise, enhances its competitive positioning, and injects tangible value into its financials— all of which bode well for sustained growth in China’s rapidly evolving pharmaceutical landscape.